21:35:35 EDT Mon 19 Apr 2021
Enter Symbol
or Name
USA
CA



Z:MRK - MERCK & CO INC - http://www.merck.com21:35:35 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRK - Z0.177.67·77.760.177.66+0.190.28,144.7631,60160,49477.70  77.79  76.9787.80  71.71519:59:30Apr 1515 min RT 2¢

Recent Trades - Last 10 of 60494
Time ETExPriceChangeVolume
19:59:30Z77.690.222
19:58:38Z77.690.224
19:58:02Z77.680.21100
19:56:47Z77.680.21100
19:55:46Z77.690.22200
19:50:59Z77.580.11650
19:49:35Z77.670.2060
19:49:35Z77.680.2128
19:49:35Z77.690.2212
19:37:20Z77.600.1320

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-04-15 06:46U:MRKNews ReleaseMerck to Discontinue Development of MK-7110 for COVID-19
2021-04-15 06:45U:MRKNews ReleaseMerck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
2021-04-14 08:00U:MRKNews ReleaseMerck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
2021-04-08 20:31U:MRKNews ReleaseOrganon Announces Pricing of Senior Notes Offering
2021-04-08 06:45U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
2021-04-06 16:10U:MRKNews ReleaseOrganon Announces Proposed Senior Notes Offering
2021-04-01 08:30U:MRKNews ReleaseMerck Completes Acquisition of Pandion Therapeutics
2021-03-30 07:30U:MRKNews ReleaseMerck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
2021-03-30 06:45U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA ® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer
2021-03-29 16:15U:MRKNews ReleaseMerck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2021-03-29 06:45U:MRKNews ReleaseMerck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
2021-03-24 06:45U:MRKNews ReleaseMerck Appoints Caroline Litchfield Chief Financial Officer
2021-03-23 06:45U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma